1.03 (4.05%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Hemab Therapeutics Holdings, Inc.
Telephone
1.617.553.3952
Address
Suite 1220, 101 Main Street, Cambridge, MA 02142
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 23 - 36.61
Trade Value (12mth)
US$221,673.00
1 week
-9.37%
1 month
0%
YTD
-25.18%
1 year
0%
All time high
36.61
EPS 3 yr Growth
N/A
EBITDA Margin
0.00%
Operating Cashflow
-$61m
Free Cash Flow Return
-44.90%
ROIC
-46.70%
Interest Coverage
0.00
Quick Ratio
18.00
Shares Outstanding (Fully Diluted)
2m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Historical data
Forecast data
| 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | US$ |  | | | | N/A | -24.25 | -31.82 | | | | ||
EPS (Fully Diluted) | US$ | | | | | N/A | -24.25 | -31.82 | | | | ||
Growth | % | | | | | N/A | N/A | -31.2 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
